View on Pubmed.gov 12384552 View on doi.org
High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers.
- The Picower Institute for Medical Research NY, Manhasset, New York 10030, USA.
Abstract
Tumor cells maintain an especially high glycolytic rate to supply the anabolic precursors essential for de novo nucleotide synthesis. We recently cloned an inducible isozyme of 6-phosphofructo-2 kinase (iPFK-2) that bears an oncogene-like regulatory element in its mRNA and functions to produce fructose-2,6-bisphosphate, which is a powerful allosteric activator of glycolysis. Rapidly proliferating cancer cells constitutively express iPFK-2 in vitro, and inhibition of iPFK-2 expression decreases tumor growth in experimental animal models. We report herein that the expression of iPFK-2 mRNA and protein, as assessed by in situ hybridization and immunohistochemistry, is increased in many human cancers when compared with corresponding normal tissues. In particular, iPFK-2 expression was found to be markedly elevated in multiple aggressive primary neoplasms, including colon, breast, ovarian, and thyroid carcinomas. iPFK-2 mRNA and protein expression were induced by hypoxia in cultured human colon adenocarcinoma cells, and an examination of normal lung fibroblasts showed that iPFK-2 and fructose-2,6-bisphosphate levels increased specifically during the S phase of the cell cycle. These data indicate that iPFK-2 is abundantly expressed in human tumors in situ and may serve as an essential regulator of glycolysis during cell cycle progression and growth in an hypoxic microenvironment.
References
Cited by 331 citations (total)
Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review
Hypoxia, glucose metabolism and the Warburg's effect.
Electronic publication date March 22, 2008
Ramon Bartrons [...] Jaime Caro et al.
As described by Warburg more than 50 years ago, tumour cells maintain a high glycolytic rate even in conditions of...
Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review
Is cancer a metabolic disease?
Electronic publication date August 19, 2014
Hilary A Coller
Although cancer has historically been viewed as a disorder of proliferation, recent evidence has suggested that it should also be...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
Substances
- •
- •
- •
- •